Sign in Subscribe

Nurix and Roche Team Up in Massive $2.3B Partnership for Next-Gen Blood Cancer Treatment

Nurix Therapeutics gets $700M upfront in a potential $2.3B partnership with Roche to co-develop bexobrutideg, a next-gen oral BTK degrader for CLL, MS, and immunology.

Nurix and Roche Team Up in Massive $2.3B Partnership for Next-Gen Blood Cancer Treatment
Credit: Bloomberg
Already have an account? Sign in.